Alflutinib

• CAT Number: I021759
• CAS Number: 1869057-83-9
• Molecular Formula: C28H31F3N8O2
• Molecular Weight: 568.61
• Purity: 98%
• Synonyms: Alflutinib, AST-2818, AST2818, AST 2818
• Target: Protein Tyrosine Kinase/RTK
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: N-[2-[2-(dimethylamino)ethyl-methylamino]-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-6-(2,2,2-trifluoroethoxy)pyridin-3-yl]prop-2-enamide
• InChI: InChI=1S/C28H31F3N8O2/c1-6-24(40)33-21-15-22(26(41-17-28(29,30)31)36-25(21)38(4)14-13-37(2)3)35-27-32-12-11-20(34-27)19-16-39(5)23-10-8-7-9-18(19)23/h6-12,15-16H,1,13-14,17H2,2-5H3,(H,33,40)(H,32,34,35)
• InChIKey: GHKOONMJXNWOIW-UHFFFAOYSA-N
• SMILES: CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(N=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OCC(F)(F)F

Alflutinib（Cat No.:I021759）is a novel, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being investigated for its potential in treating non-small cell lung cancer (NSCLC) and other EGFR-mutant cancers. It works by blocking the activity of the mutated EGFR, which is responsible for promoting the growth and proliferation of cancer cells. Alflutinib is designed to overcome resistance to first-generation EGFR inhibitors, offering potential benefits in patients with advanced or resistant forms of cancer. Clinical trials are ongoing to assess its safety, efficacy, and optimal treatment regimens.